Tag Archives: Fidaxomicin

Fidaxomicin Clinical Trials


Good after-effects were appear by the aggregation in 2009 from a North American appearance III balloon comparing it with articulate vancomycin for the analysis of Clostridium difficile infection (CDI) The extraction met its primary endpoint of analytic cure, assuming that fidaxomicin was non-inferior to articulate vancomycin (92.1% vs. 89.8%). In addition, the extraction met its accessory endpoint of recurrence: 13.3% of the capacity had a ceremony with fidaxomicin vs. 24.0% with articulate vancomycin. The extraction aswell met its basic endpoint of all-around cure (77.7% for fidaxomicin vs. 67.1% for vancomycin). Analytic cure was authentic as patients acute no added CDI analysis two canicule afterwards achievement of extraction medication. All-around cure was authentic as patients who were convalescent at the end of analysis and did not accept a ceremony in the next four weeks.

Fidaxomicin was apparent to be as acceptable as the accepted standard-of-care, vancomycin, for alleviative CDI in a Appearance III balloon appear in February 2011. The authors aswell appear decidedly beneath recurrences of infection, a common botheration with C. difficile, and agnate biologic ancillary effects.